Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 ...

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at uk.finance.yahoo.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

Bayer's KERENDIA® (finerenone) has received FDA approval as the first new treatment in 30 years for adults with chronic kidney disease and type 1 diabetes.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You have a new approved treatment option to explore for chronic kidney disease with type 1 diabetes, opening clinical and commercial doors that have been closed for 30 years. This shifts competition in nephrology biotech and may unlock partnerships or new trial designs.

◆ Coverage

2 sources · 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalckdtype-1-diabetesfinerenonebayerfda